RJFSA
STML

Raymond James Financial Services Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Raymond James Financial Services Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,116
Closed -$189K – 2785
2017
Q4 		$189K Buy
+12,116
New +$162K ﹤0.01% 2287

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Raymond James Financial Services Advisors's STML Position: Q1 2018 in Review

Raymond James Financial Services Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q1 2018, closing a stake of 12,116 shares — an estimated $189K sold.

Raymond James Financial Services Advisors first reported a position in STML in Q4 2017 and held it in 1 quarter. The position peaked at $189K in Q4 2017. 82 funds tracked by Wall St. Rank hold STML as of Q1 2018.

  • Raymond James Financial Services Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 12,116 Stemline Therapeutics, Inc. shares in Q1 2018, an estimated $189K.
  • Raymond James Financial Services Advisors first reported a position in Stemline Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Stemline Therapeutics, Inc. position peaked at $189K in Q4 2017.
  • 82 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2018, filed 16 Apr 2018.